California State Teachers Retirement System Purchases 2,998 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

California State Teachers Retirement System raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 199,861 shares of the biopharmaceutical company's stock after acquiring an additional 2,998 shares during the quarter. California State Teachers Retirement System owned approximately 0.15% of Alnylam Pharmaceuticals worth $60,164,157 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $895,816,000. Legal & General Group Plc acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. Bank of New York Mellon Corp acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $148,128,000. Canada Pension Plan Investment Board bought a new position in Alnylam Pharmaceuticals in the second quarter worth $100,618,000. Finally, Korea Investment CORP acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $74,553,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. Weiss Ratings upgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, July 31st. Chardan Capital reissued a "buy" rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Citigroup lowered their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an "equal weight" rating on the stock in a research note on Friday, August 14th. Finally, Barclays cut their target price on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating for the company in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $376.67.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY traded down $6.89 during midday trading on Tuesday, reaching $243.10. 696,732 shares of the company's stock traded hands, compared to its average volume of 1,452,514. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a market cap of $32.53 billion, a P/E ratio of 45.14 and a beta of 0.31. The company has a fifty day simple moving average of $253.16 and a two-hundred day simple moving average of $288.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company's quarterly revenue was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.